Tenax Therapeutics, Inc. (TENX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tenax Therapeutics, Inc. (TENX) trades at $17.74 with AI Score 52/100 (Grade B). Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing treatments for cardiovascular and pulmonary diseases. Market cap: $305.10M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for TENX: TENX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TENX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
TENX: the 1 perspectives are evenly split.
How is this calculated? →Tenax Therapeutics, Inc. (TENX) Healthcare & Pipeline Overview
Tenax Therapeutics, Inc. is a specialty pharmaceutical company developing and commercializing therapies for cardiovascular and pulmonary diseases. Their pipeline focuses on pulmonary hypertension treatments, including TNX-103, TNX-102 (levosimendan), and TNX-201 (imatinib), positioning them in a niche segment of the biotechnology sector.
What Is the Investment Thesis for TENX?
Tenax Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on developing treatments for pulmonary hypertension and related conditions addresses a significant unmet medical need. Key value drivers include the successful completion of clinical trials for TNX-103, TNX-102 (levosimendan), and TNX-201 (imatinib), leading to potential FDA approval and commercialization. The company's small size and limited resources present challenges, but successful drug development could result in substantial returns. The current market capitalization of $305.10M reflects the speculative nature of the investment, with potential upside dependent on positive clinical trial outcomes and regulatory approvals. Upcoming clinical trial results will be critical catalysts for the stock. However, potential setbacks in clinical trials or regulatory hurdles represent significant risks.
Based on FMP financials and quantitative analysis
TENX Key Highlights
- Tenax Therapeutics focuses on cardiovascular and pulmonary diseases, a market with significant unmet needs.
- TNX-102 (levosimendan) has completed Phase II clinical trials, showing promise for treating pulmonary hypertension associated with heart failure with preserved ejection fraction.
- TNX-201 (imatinib) is a tyrosine kinase inhibitor being developed for pulmonary arterial hypertension, representing a novel approach to treatment.
- The company's small size (4 employees) allows for agility but also presents resource constraints.
- Tenax Therapeutics operates in the United States and Canada, targeting specific patient populations with limited treatment options.
Who Are TENX's Competitors?
TENX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ANAB AnaptysBio, Inc. | $65.78 | -2.30% | $2.84B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $24.63 | +5.96% | $2.18B | 79 |
| ABVX Abivax S.A. | $138.54 | -2.55% | 10B | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $3.95 | +0.25% | $372.56M | 76 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| MIRM Mirum Pharmaceuticals, Inc. | $128.31 | +5.25% | $6.44B | 68 |
| FREQ Frequency Therapeutics | $0.30 | +4.76% | $10.94M | 68 |
| IVBXF Innovent Biologics, Inc. | $11.30 | +11.33% | $19.60B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TENX's Key Strengths?
- Focus on cardiovascular and pulmonary diseases with unmet needs.
- Pipeline includes TNX-103, TNX-102 (levosimendan), and TNX-201 (imatinib).
- Completed Phase II clinical trials for TNX-102 (levosimendan).
- Experienced management team with expertise in drug development.
What Are TENX's Weaknesses?
- Small company with limited resources (4 employees).
- Reliance on successful clinical trial outcomes and regulatory approvals.
- Limited commercialization experience.
- High cash burn rate.
What Could Drive TENX Stock Higher?
- Clinical trial results for TNX-103 in pulmonary hypertension associated with heart failure with preserved ejection fraction.
- Clinical trial results for TNX-201 (imatinib) in pulmonary arterial hypertension.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
- Regulatory submissions and approvals for pipeline products.
What Are the Key Risks for TENX?
- Negative return on equity (-56.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to achieve positive clinical trial results for TNX-103, TNX-102, or TNX-201.
- Regulatory hurdles and delays in drug approval.
- Competition from larger pharmaceutical companies with greater resources.
- Limited financial resources and high cash burn rate.
- Patent expirations and generic competition.
What Are the Growth Opportunities for TENX?
- Expansion into New Therapeutic Areas: Tenax Therapeutics could leverage its expertise in cardiovascular and pulmonary diseases to expand into new therapeutic areas, such as chronic obstructive pulmonary disease (COPD) or heart failure. The global COPD market is projected to reach $16.8 billion by 2027, presenting a significant growth opportunity. This expansion would require additional research and development efforts, but could diversify the company's pipeline and reduce its reliance on pulmonary hypertension treatments. Timeline: 3-5 years.
- Geographic Expansion: Currently operating in the United States and Canada, Tenax Therapeutics could expand its geographic reach to Europe or Asia. The European market for pulmonary hypertension treatments is estimated at $1.5 billion, offering a substantial growth opportunity. This expansion would require navigating regulatory hurdles and establishing distribution networks in new markets. Timeline: 2-4 years.
- Strategic Partnerships and Collaborations: Tenax Therapeutics could pursue strategic partnerships and collaborations with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its pipeline products. These partnerships could provide access to additional funding, expertise, and resources. This collaborative approach could enhance the company's ability to bring its therapies to market more quickly and efficiently. Timeline: Ongoing.
- Acquisition of Complementary Technologies or Assets: Tenax Therapeutics could acquire complementary technologies or assets to strengthen its pipeline and expand its capabilities. This could include acquiring companies with promising drug candidates in related therapeutic areas or technologies that enhance drug delivery or diagnostics. Such acquisitions could provide synergies and accelerate the company's growth. Timeline: 2-3 years.
- Orphan Drug Designation and Accelerated Approval Pathways: Tenax Therapeutics can leverage orphan drug designations and accelerated approval pathways for its therapies targeting rare diseases within the cardiovascular and pulmonary space. These regulatory mechanisms can expedite the drug development and approval process, providing a competitive advantage and faster market access. This strategy is particularly relevant for TNX-201 (imatinib) in treating pulmonary arterial hypertension. Timeline: Ongoing.
What Opportunities Does TENX Have?
- Expansion into new therapeutic areas within cardiovascular and pulmonary diseases.
- Strategic partnerships and collaborations with larger pharmaceutical companies.
- Acquisition of complementary technologies or assets.
- Orphan drug designation and accelerated approval pathways.
What Threats Does TENX Face?
- Competition from larger pharmaceutical companies with greater resources.
- Failure to achieve positive clinical trial results.
- Regulatory hurdles and delays in drug approval.
- Patent expirations and generic competition.
What Are TENX's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Specialized expertise in cardiovascular and pulmonary diseases.
- Established relationships with key opinion leaders in the medical community.
- Focus on addressing unmet medical needs in specific disease subtypes.
What Does TENX Do?
Tenax Therapeutics, Inc., founded in 1967 and headquartered in Morrisville, North Carolina, is a specialty pharmaceutical company dedicated to identifying, developing, and commercializing innovative products for the treatment of cardiovascular and pulmonary diseases. Originally named Oxygen Biotherapeutics, Inc., the company rebranded to Tenax Therapeutics in September 2014, signaling a strategic shift in its focus and direction. The company's core mission is to address unmet medical needs in the treatment of pulmonary hypertension and related conditions. Tenax Therapeutics' pipeline includes several promising drug candidates. TNX-103 and TNX-102 (levosimendan) have completed Phase II clinical trials and are being developed for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (HFpEF) and associated pulmonary hypertension. TNX-201 (imatinib), a tyrosine kinase inhibitor, is being developed for the treatment of pulmonary arterial hypertension (PAH). These therapies represent potential advancements in the treatment of these debilitating conditions. The company operates primarily in the United States and Canada, targeting specific patient populations with limited treatment options. Tenax Therapeutics aims to improve the lives of patients suffering from cardiovascular and pulmonary diseases through the development and commercialization of novel therapies. Their focus on pulmonary hypertension and related conditions positions them within a specialized segment of the pharmaceutical industry, where they strive to offer innovative solutions and address critical unmet medical needs.
What Products and Services Does TENX Offer?
- Develops TNX-103 for pulmonary hypertension associated with heart failure with preserved ejection fraction.
- Develops TNX-102 (levosimendan) for pulmonary hypertension associated with heart failure with preserved ejection fraction.
- Develops TNX-201 (imatinib) for pulmonary arterial hypertension.
- Identifies potential products for cardiovascular diseases.
- Identifies potential products for pulmonary diseases.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
How Does TENX Make Money?
- Focuses on developing and commercializing pharmaceutical products.
- Generates revenue through the sale of approved therapies.
- Invests in research and development to expand its product pipeline.
- Seeks partnerships and collaborations to accelerate drug development and commercialization.
What Industry Does TENX Operate In?
Tenax Therapeutics operates within the biotechnology industry, specifically targeting the cardiovascular and pulmonary disease market. This market is characterized by significant unmet medical needs, particularly in the treatment of pulmonary hypertension and related conditions. The industry is highly competitive, with numerous pharmaceutical companies and biotechnology firms vying to develop innovative therapies. Key trends include the increasing prevalence of cardiovascular and pulmonary diseases, advancements in drug development technologies, and a growing emphasis on personalized medicine. Tenax Therapeutics' focus on specific disease subtypes and novel therapeutic approaches positions it within a niche segment of this dynamic landscape.
Who Are TENX's Key Customers?
- Patients with pulmonary hypertension associated with heart failure with preserved ejection fraction.
- Patients with pulmonary arterial hypertension.
- Hospitals and clinics that treat cardiovascular and pulmonary diseases.
- Physicians who prescribe medications for these conditions.
ROE -56%Key Financial Metrics
Return on equity for Tenax Therapeutics, Inc. stands at -56.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -47.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -14.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 14.52 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.3%, the inverse of the P/E and a quick read on earnings relative to price.
Tenax Therapeutics, Inc. (TENX) Valuation Context
Valued at $305.10M, TENX is classified as a small-cap stock. Relative to its peer group, TENX's quantitative score of 52/100 is below the peer average of 76/100.
Company Profile
Tenax Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Chapel Hill, US. The company is led by CEO Christopher T. Giordano. TENX has traded publicly since 1994.
F-Score 1/9Financial Health
Tenax Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 14.98 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Tenax Therapeutics, Inc. revenue of about $4.2M for fiscal 2026, with EPS near $-1.84. The estimate reflects 6 contributing analysts.
TENX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Tenax's future, indicating executives believe in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting the innovative therapies in development that could address unmet medical needs.
- Recent partnerships with research institutions have bolstered credibility, enhancing the perception of Tenax's pipeline.
- Market interest in biotech has surged, with Tenax positioned to benefit from increased investor focus on novel therapeutics.
Bear Case
- Concerns about the competitive landscape in the biotech sector have emerged, with analysts questioning Tenax's ability to differentiate its products.
- Social sentiment has shown some skepticism regarding the timelines for clinical trials, leading to doubts about near-term catalysts.
- Recent regulatory hurdles faced by similar companies have raised fears about the approval process for Tenax's therapies.
- Overall market volatility has led to cautious sentiment, with investors wary of potential downturns in the biotech space affecting Tenax.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
TENX Latest News
-
Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday
benzinga · Jul 2, 2026
-
Earnings Scheduled For May 12, 2026
benzinga · May 12, 2026
TENX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TENX.
Price Targets
Wall Street price target analysis for TENX.
TENX MoonshotScore
What does this score mean?
The MoonshotScore rates TENX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Christopher T. Giordano
Unknown
Information about Christopher T. Giordano's background is not available in the provided data. Without additional context, it is impossible to provide a detailed career history, education, previous roles, or credentials.
Track Record: Information about Christopher T. Giordano's track record is not available in the provided data. Without additional context, it is impossible to provide key achievements, strategic decisions, or company milestones under their leadership.
What Investors Ask About Tenax Therapeutics, Inc. (TENX) — Healthcare
What does Tenax Therapeutics, Inc. do?
Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for cardiovascular and pulmonary diseases. The company's pipeline includes TNX-103 and TNX-102 (levosimendan), which have completed Phase II clinical trials for pulmonary hypertension associated with heart failure with preserved ejection fraction, and TNX-201 (imatinib) for pulmonary arterial hypertension. Tenax aims to address unmet medical needs in these therapeutic areas by developing novel therapies and bringing them to market in the United States and Canada.
What do analysts say about TENX stock?
Analyst coverage of Tenax Therapeutics (TENX) is limited, reflecting the company's small size and early stage of development. The stock is considered a high-risk, high-reward investment, with potential upside dependent on positive clinical trial outcomes and regulatory approvals. Key valuation metrics are not readily available due to the company's pre-revenue status. Growth considerations center on the successful development and commercialization of its pipeline products, particularly TNX-103, TNX-102, and TNX-201. Analyst opinions are speculative and contingent on future clinical and regulatory milestones.
What are the main risks for TENX?
Tenax Therapeutics faces significant risks inherent in the biotechnology industry. The primary risk is the potential failure to achieve positive clinical trial results for its pipeline products, particularly TNX-103, TNX-102, and TNX-201. Regulatory hurdles and delays in drug approval also pose a substantial risk. Additionally, the company faces competition from larger pharmaceutical companies with greater resources. Limited financial resources and a high cash burn rate further exacerbate the risks. Patent expirations and generic competition could also impact future revenue streams.
What are the key factors to evaluate for TENX?
Tenax Therapeutics, Inc. (TENX) holds an AI score of 52/100 (moderate). Not financial advice.
How frequently does TENX data refresh on this page?
TENX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TENX's recent stock price performance?
Tenax Therapeutics, Inc. (TENX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on cardiovascular and pulmonary diseases with unmet needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TENX overvalued or undervalued right now?
Valuing Tenax Therapeutics, Inc. (TENX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying TENX?
Before investing in Tenax Therapeutics, Inc. (TENX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available.
- Future clinical trial results and regulatory approvals are uncertain.
- Financial projections are speculative and subject to change.